The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration

European Journal of Ophthalmology

Volumn 23, Issue 4, 2013, Pages 553-557

  Aslankurt, Murat ^a   Aslan, Lokman ^a   Aksoy, Adnan ^a   Erden, Burak ^b   Çekiç, Osman ^b  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^b OKMEYDANI TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Age related macular degeneration; Anti VEGF switch; Bevacizumab; Choroidal neovascularization; Intravitreal injection; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH INSURANCE; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84878458266     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000268     Document Type: Article

References (22)

1. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006;124: 529-35.
2. Bressler NM. Age-related macular degeneration is the lead-ing cause of blindness. JAMA 2004;291:1900-1.
3. Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseas-es Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
4. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-44.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
6. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Oph-thalmol 2011;56:95-113.
7. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
9. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neo-vascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65.
10. Holz FG, Amoaku W, Donate J, et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibi-zumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
11. Karagiannis DA, Ladas ID, Parikakis E, et al. Changing from bevacizumab to ranibizumab in age-related macular degen-eration. Is it safe? Clin Interv Aging 2009;4:457-61.
12. Karagiannis DA, Mitropoulos P, Ladas ID. Large subretinal haemorrhage following change from intravitreal bevacizum-ab to ranibizumab. Ophthalmologica 2009;223:279-82.
13. Ehlers JP, Spirn MJ, Shah CP, et al. Ranibizumab for exu-dative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors. Ophthalmic Surg Lasers Imaging 2010;41:182-9.
14. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009;29:1067-73.
15. Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Shei-dow TG. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascu-lar age-related macular degeneration. Can J Ophthalmol 2012;47:159-64.
16. Dhoot DS, Kaiser PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther 2012;12:371-81.
17. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluoro-uracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21: 60-5.
18. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coher-ence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36: 331-5.
19. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
20. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neo-vascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
21. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H. Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina 2012 Dec 5. (Epub ahead of print).
22. Yamada K, Kimoto K, Kono H, Kubota T. Switching from intravitreal ranibizumab to bevacizumab for age-related macular degeneration. ISRN Ophthalmology 2011. Avail-able at: http://www.isrn.com/journals/ophthalmology/2011/916789/.